Corona Remedies is an India-focused branded pharmaceutical formulations manufacturer engaged in developing, producing and marketing products across women’s healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. As of June 30, 2025, it offers 71 brands across these segments. For MAT June 2025, women’s healthcare contributed 28.56% (₹4,080.26 million), cardio-diabeto 23.38% (₹3,339.96 million), pain management 11.79% (₹1,684.38 million) and urology 4.53% (₹646.65 million) to its domestic sales.
Price Band₹1008 - ₹1062 |
Dates08 Dec - 10 Dec |
GMP₹365 (34.37%) |
Subscriptions- |
Issue Size₹655.37 Crs |
Corona Remedies IPO Objects
The issue is a complete Offer for Sale (OFS). The company will not receive any funds from the issue, entire proceeds will be received by the Selling Shareholder(s).
Corona Remedies IPO Details
Price Band₹1008 - ₹1062 |
Listing AtNSE & BSE |
IPO Issue Type100% Book Built Offer |
Fresh Issue(0.00 Shares) |
Offer For Sale₹655.37 Cr ( Shares) |
Total Issue₹655.37 Cr ( Shares) |
Face Value₹10 per equity share |
Corona Remedies IPO Lot Information
| Investor Category | Lot | Shares | Amount | |
|---|---|---|---|---|
| Retail |
Minimum
1
14
14,868
Maximum
13
182
1,93,284
|
|||
| Small HNI |
Minimum
14
196
2,08,152
Maximum
67
938
9,96,156
|
|||
| Big HNI |
Minimum
68
952
10,11,024
|
|||
Corona Remedies IPO GMP
The estimated Grey Market Premium of Corona Remedies IPO is ₹365 per share (34.37%)
Category Allocation
| Particulars | Allocation |
|---|---|
| QIBs | Not more than 50% of Net Offer |
| Big HNIs (NII) | Not less than 10% of Net Offer |
| Small HNIs (NII) | Not less than 5% of Net Offer |
| Retail | Not less than 35% of Net Offer |
Corona Remedies IPO Financials
| Particulars | Jun-25 | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|---|
| Revenue from Operations | 346.54 | 1,196.42 | 1,014.47 | 884.05 |
| Profit after Tax | 46.20 | 149.43 | 90.50 | 84.93 |
| Net Worth | 607.02 | 606.34 | 480.41 | 408.52 |
| Total Borrowing | 106.65 | 62.70 | 134.14 | 2.33 |
| Total Assets | 1,012.38 | 929.86 | 830.58 | 595.02 |
| NAV per share (in ₹) | 99.25 | 99.14 | 78.55 | 70.06 |
| EPS - Basic (in ₹) | 7.55 | 24.43 | 14.80 | 14.57 |
The financial information presented is on a consolidated basis.
Key Performance Indicators
| KPI | Values |
|---|---|
| EBITDA | 20.55% |
| PAT | 12.49% |
| ROE | 27.50% |
| ROCE | 41.32% |
| PE Ratio | 43.47 |
| PB Ratio | 10.71 |
| Mkt Cap (in Crs.) | 6,495.20 |
- All the data pertains to FY 2024-25.
- PE, PB, and market capitalization are calculated based on the Upper Price Band.
Corona Remedies IPO Peer Comparision
| Particulars | CORONA Remedies | Abbott India | Alkem Laboratories | Eris Lifesciences | GlaxoSmithKline | J.B. Chemicals | Mankind Pharma | Pfizer | Sanofi India | Torrent Pharma |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Ops (in Crs.) | 1,196.42 | 6,409.15 | 12,964.52 | 2,893.64 | 3,749.21 | 3,917.99 | 12,207.44 | 2,281.35 | 2,013.20 | 11,516.09 |
| PAT (In Crs.) | 149.43 | 1,414.44 | 2,215.38 | 374.67 | 927.58 | 659.58 | 2,011.12 | 767.60 | 413.50 | 1,911.25 |
| EPS - Basic | 24.43 | 665.62 | 181.11 | 25.85 | 54.76 | 42.45 | 49.28 | 167.79 | 179.46 | 56.47 |
| NAV per share | 99.14 | 1,992.14 | 1,002.37 | 209.73 | 115.19 | 220.88 | 352.51 | 921.88 | 373.68 | 224.28 |
| RONW | 24.65% | 33.41% | 18.07% | 12.21% | 47.54% | 19.21% | 13.89% | 18.20% | 48.05% | 25.18% |
| EBITDA | 20.55% | 30.70% | 19.40% | 35.20% | 31.40% | 26.30% | 24.80% | 32.00% | 25.20% | 0.00% |
| PAT Margin | 12.49% | 22.07% | 16.70% | 12.95% | 25.00% | 16.83% | 16.30% | 33.65% | 15.58% | 16.60% |
| Price to earning (PE) | 43.47 | 45.17 | 31.39 | 61.81 | 46.87 | 42.60 | 45.77 | 29.63 | 24.47 | 65.91 |
All information pertains to FY 2024-25.The PE ratio is calculated using the Upper Price Band for the Issuer and the closing price as of November 28, 2025, for Peers
Corona Remedies IPO Peer Comparision
| Particulars | CORONA Remedies |
|---|---|
| Revenue from Ops (in Crs.) | 1,196.42 |
| PAT (In Crs.) | 149.43 |
| EPS - Basic | 24.43 |
| NAV per share | 99.14 |
| RONW | 24.65% |
| EBITDA | 20.55% |
| PAT Margin | 12.49% |
| Price to earning (PE) | 43.47 |
| Abbott India | Alkem Laboratories | Eris Lifesciences | GlaxoSmithKline | J.B. Chemicals | Mankind Pharma | Pfizer | Sanofi India | Torrent Pharma |
|---|---|---|---|---|---|---|---|---|
| 6,409.15 | 12,964.52 | 2,893.64 | 3,749.21 | 3,917.99 | 12,207.44 | 2,281.35 | 2,013.20 | 11,516.09 |
| 1,414.44 | 2,215.38 | 374.67 | 927.58 | 659.58 | 2,011.12 | 767.60 | 413.50 | 1,911.25 |
| 665.62 | 181.11 | 25.85 | 54.76 | 42.45 | 49.28 | 167.79 | 179.46 | 56.47 |
| 1,992.14 | 1,002.37 | 209.73 | 115.19 | 220.88 | 352.51 | 921.88 | 373.68 | 224.28 |
| 33.41% | 18.07% | 12.21% | 47.54% | 19.21% | 13.89% | 18.20% | 48.05% | 25.18% |
| 30.70% | 19.40% | 35.20% | 31.40% | 26.30% | 24.80% | 32.00% | 25.20% | 0.00% |
| 22.07% | 16.70% | 12.95% | 25.00% | 16.83% | 16.30% | 33.65% | 15.58% | 16.60% |
| 45.17 | 31.39 | 61.81 | 46.87 | 42.60 | 45.77 | 29.63 | 24.47 | 65.91 |
All information pertains to FY 2024-25.The PE ratio is calculated using the Upper Price Band for the Issuer and the closing price as of November 28, 2025, for Peers
Promoter Details
| Name | Shareholding |
|---|---|
| Kirtikumar Mehta | 22.00% |
| Niravkumar Mehta | 22.00% |
| Ankur Mehta | 22.00% |
| Others | 6.50% |
| Total | 72.50% |
Management Details
| Name | Designation |
|---|---|
| Kirtikumar Mehta | Chairman |
| Niravkumar Mehta | MD & CEO |
| Bhavin Bhagat | CFO |
Company Details
Name: Corona Remedies Limited
Address: CORONA House, C – Mondeal
Business Park, Near Gurudwara
S. G. Highway, Thaltej
Ahmedabad 380 059, Gujarat, India
Number: 79 4023 3000
Email: complianceofficer@coronaremedies.com
Website: https://www.coronaremedies.com/
Book Running Lead Managers (BRLMs)
RTAs
Bigshare Services
Visit WebsiteFrequently Asked questions?
Find answers to common questions that come in your mind related to IPO.
Corona Remedies IPO is a Mainboard IPO having an issue size of Rs. ₹655.37 Crs. Corona Remedies IPO is priced at ₹1008 - ₹1062 per share. The issue opens on 08 Dec 25 and closes on 10 Dec 25.
Corona Remedies IPO opens on 08 Dec 25 and closes on 10 Dec 25.
The estimated Grey Market Premium of Corona Remedies IPO is ₹365 per share (34.37%).
The minimum lot size of Corona Remedies IPO is 14 shares & the minimum application amount is Rs. 14868.
The allotment date of Corona Remedies IPO is 11 Dec 25.
The listing date of Corona Remedies IPO is 15 Dec 25.
Corona Remedies IPO is subscribed -.
Corona Remedies IPO is priced at ₹1008 - ₹1062 per share.
Click the allotment link on Corona Remedies IPO page of IPO360.
- Go to Kite App → Tap on Bids → Tap on IPO
- Select the IPO → Tap on apply → Enter UPI ID
- Enter Qty and Price
- Submit the application
- Approve the UPI Mandate on your UPI app
- Go to Groww App → Stocks Section → Select IPO option
- Select the IPO you want to apply
- Enter your bid details and price
- Enter UPI ID & submit
- Approve the UPI Mandate on your UPI app
- Log in to your bank's net banking portal.
- Navigate to the 'IPO' or 'ASBA' section.
- Select Corona Remedies IPO from the list of available IPOs.
- Enter the required details: Bid quantity, Price, DP ID & Client ID, etc
- Submit the application.
- Money will remain blocked till the refund date
We are a one-stop destination for all your IPO needs. Get reliable, accurate, and timely information for all the IPOs in India!